Company intelligence / Profile preview

Homology Medicines

Bedford, Massachusetts, United Statesorpha.net ↗

Ownership: Public · FIXX
Employees: ~100
Development stage: Preclinical

Overview

The company had encouraging initial data from the first dose cohort of the pheEDIT clinical trial evaluating HMI-103 gene editing candidate for PKU. As of July 26, 2023, HMI-103 was generally well-tolerated in all three participants, with two participants achieving meaningful reductions in plasma Phe levels[10].

Therapeutic areas: HematologyRare DiseasesNeurologyMetabolic Disorders
Modalities: Gene therapyGene editingGTx-mAb (gene therapy to produce antibodies)
Industry: Biotech

Drug pipeline

1 asset

HMI-102

Pre-clinical

Indications: Phenylketonuria

Partnerships

Oxford Biomedica (formed Oxford Biomedica Solutions)

Financials

Market cap: $121.2K
Enterprise value: $121.2K

Beyond the preview

Go deeper on Homology Medicines.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Homology Medicines.

Explore the full profile